Crossmark Global Holdings, Inc. Exelixis, Inc. Transaction History

Crossmark Global Holdings, Inc.

$5.22 Billion
Q1 2024

A detailed history of Crossmark Global Holdings, Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, Crossmark Global Holdings, Inc. holds 55,108 shares of EXEL stock, worth $1.22 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

55,108

Previous 59,188 6.89%

Holding current value

$1.22 Million

Previous $1.42 Million 7.82%

% of portfolio

0.03%

Previous 0.03%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$20.17 - $23.93 $82,293 - $97,634	-4,080 Reduced 6.89%	55,108 $1.31 Million
Q4 2023 Feb 13, 2024	BUY	$19.25 - $24.13 $140,679 - $176,342	7,308 Added 14.09%	59,188 $1.42 Million
Q3 2023 Nov 08, 2023	BUY	$19.04 - $22.74 $428,895 - $512,241	22,526 Added 76.74%	51,880 $1.12 Million
Q2 2023 Jul 31, 2023	SELL	$18.17 - $20.48 $11,610 - $13,086	-639 Reduced 2.13%	29,354 $583,000
Q1 2023 May 12, 2023	SELL	$16.3 - $19.41 $8,198 - $9,763	-503 Reduced 1.65%	29,993 $582,000

Q4 2022 Jan 19, 2023	SELL	$14.96 - $17.39 $2,752 - $3,199	-184 Reduced 0.6%	30,496 $489,000
Q3 2022 Nov 01, 2022	SELL	$15.68 - $22.27 $5,801 - $8,239	-370 Reduced 1.19%	30,680 $481,000
Q2 2022 Jul 29, 2022	SELL	$17.44 - $23.16 $4,534 - $6,021	-260 Reduced 0.83%	31,050 $646,000
Q1 2022 May 11, 2022	BUY	$17.03 - $22.67 $13,624 - $18,136	800 Added 2.62%	31,310 $709,000
Q4 2021 Jan 10, 2022	SELL	$15.84 - $21.88 $198,633 - $274,375	-12,540 Reduced 29.13%	30,510 $558,000
Q3 2021 Oct 21, 2021	BUY	$16.3 - $21.14 $701,715 - $910,077	43,050 New	43,050 $910,000
Q3 2021 Oct 13, 2021	SELL	$16.3 - $21.14 $702,367 - $910,922	-43,090 Closed	0 $0
Q2 2021 Jul 21, 2021	BUY	$17.95 - $25.56 $14,360 - $20,448	800 Added 1.89%	43,090 $785,000
Q1 2021 Apr 15, 2021	BUY	$20.53 - $25.22 $4,516 - $5,548	220 Added 0.52%	42,290 $955,000
Q4 2020 Jan 14, 2021	BUY	$18.39 - $24.8 $96,731 - $130,448	5,260 Added 14.29%	42,070 $844,000
Q3 2020 Oct 08, 2020	BUY	$20.67 - $26.94 $1,860 - $2,424	90 Added 0.25%	36,810 $900,000
Q2 2020 Aug 14, 2020	BUY	$16.46 - $27.42 $45,758 - $76,227	2,780 Added 8.19%	36,720 $872,000
Q4 2019 Feb 06, 2020	BUY	$15.15 - $18.89 $118,776 - $148,097	7,840 Added 30.04%	33,940 $598,000
Q3 2019 Oct 09, 2019	SELL	$17.68 - $22.65 $21,569 - $27,633	-1,220 Reduced 4.47%	26,100 $462,000
Q2 2019 Jul 09, 2019	SELL	$18.93 - $24.75 $2,366 - $3,093	-125 Reduced 0.46%	27,320 $584,000
Q1 2019 May 02, 2019	SELL	$19.6 - $24.76 $980 - $1,238	-50 Reduced 0.18%	27,445 $653,000
Q4 2018 Jan 31, 2019	SELL	$13.65 - $21.8 $242,014 - $386,514	-17,730 Reduced 39.2%	27,495 $541,000
Q3 2018 Nov 08, 2018	BUY	$15.87 - $22.4 $717,720 - $1.01 Million	45,225 New	45,225 $801,000
Q1 2018 Apr 16, 2018	SELL	$22.15 - $31.89 $220,171 - $316,986	-9,940 Closed	0 $0
Q4 2017 Feb 05, 2018	BUY	$24.23 - $30.93 $2,301 - $2,938	95 Added 0.96%	9,940 $302,000
Q3 2016 Oct 25, 2017	BUY	N/A	9,845	9,845 $239,000

Others Institutions Holding EXEL

# of Institutions

460

Shares Held

246M

Call Options Held

1.7M

Put Options Held

1.02M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $7.13B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.

Account

Crossmark Global Holdings, Inc. Exelixis, Inc. Transaction History